BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trebicka J, Krag A, Gansweid S, Schiedermaier P, Strunk HM, Fimmers R, Strassburg CP, Bendtsen F, Møller S, Sauerbruch T. Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension. PLoS One. 2013;8:e83341. [PMID: 24386183 DOI: 10.1371/journal.pone.0083341] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Gustot T, Fernandez J, Szabo G, Albillos A, Louvet A, Jalan R, Moreau R, Moreno C. Sepsis in alcohol-related liver disease. J Hepatol. 2017;67:1031-1050. [PMID: 28647569 DOI: 10.1016/j.jhep.2017.06.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 11.3] [Reference Citation Analysis]
2 Praktiknjo M, Abu-Omar J, Chang J, Thomas D, Jansen C, Kupczyk P, Schepis F, Garcia-Pagan JC, Merli M, Meyer C, Strassburg CP, Pieper CC, Trebicka J. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep 2021;3:100264. [PMID: 34013182 DOI: 10.1016/j.jhepr.2021.100264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Berres ML, Lehmann J, Jansen C, Görtzen J, Meyer C, Thomas D, Zimmermann HW, Kroy D, Schumacher F, Strassburg CP, Sauerbruch T, Trautwein C, Wasmuth HE, Trebicka J. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Liver Int 2016;36:386-94. [PMID: 26212075 DOI: 10.1111/liv.12922] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
4 Jansen C, Eischeid H, Goertzen J, Schierwagen R, Anadol E, Strassburg CP, Sauerbruch T, Odenthal M, Trebicka J. The role of miRNA -34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS. PLoS One. 2014;9:e103779. [PMID: 25068403 DOI: 10.1371/journal.pone.0103779] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
5 Queck A, Thomas D, Jansen C, Schreiber Y, Rüschenbaum S, Praktiknjo M, Schwarzkopf KM, Mücke MM, Schierwagen R, Uschner FE, Meyer C, Clària J, Zeuzem S, Geisslinger G, Trebicka J, Lange CM. Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. PLoS One 2019;14:e0222840. [PMID: 31644538 DOI: 10.1371/journal.pone.0222840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Berres ML, Asmacher S, Lehmann J, Jansen C, Görtzen J, Klein S, Meyer C, Strunk HM, Fimmers R, Tacke F. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. J Hepatol. 2015;62:332-339. [PMID: 25457205 DOI: 10.1016/j.jhep.2014.09.032] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
7 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Yu S, Qi Y, Jiang J, Wang H, Zhou Q. APTR is a prognostic marker in cirrhotic patients with portal hypertension during TIPS procedure. Gene 2018;645:30-3. [PMID: 29274906 DOI: 10.1016/j.gene.2017.12.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
9 Manti S, Marseglia L, D’Angelo G, Filippelli M, Cuppari C, Gitto E, Romano C, Arrigo T, Salpietro C. Portal hypertension as immune mediate disease. Hepat Mon. 2014;14:e18625. [PMID: 24976841 DOI: 10.5812/hepatmon.18625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
10 Lehmann JM, Claus K, Jansen C, Pohlmann A, Schierwagen R, Meyer C, Thomas D, Manekeller S, Claria J, Strassburg CP, Trautwein C, Wasmuth HE, Berres ML, Trebicka J. Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality. Liver Int 2018;38:875-84. [PMID: 29105936 DOI: 10.1111/liv.13610] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
11 Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H. Management of refractory cirrhotic ascites: challenges and solutions. Hepat Med. 2018;10:55-71. [PMID: 30013405 DOI: 10.2147/hmer.s136578] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
12 李莹, 韩涛. 肝硬化合并细菌感染易感性机制的研究进展. 世界华人消化杂志 2015; 23(22): 3560-3566 [DOI: 10.11569/wcjd.v23.i22.3560] [Reference Citation Analysis]
13 Sauerbruch T, Trebicka J. Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep. 2014;6:95. [PMID: 25374673 DOI: 10.12703/P6-95] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
14 Steib CJ, Li H, Zhang J, Mayerle J, Ricke J, Gerbes AL, Meyer C, Zipprich A, Trebicka J. Transjugular intrahepatic portosystemic shunt for patients with liver cirrhosis: survey evaluating indications, standardization of procedures and anticoagulation in 43 German hospitals. European Journal of Gastroenterology & Hepatology 2020;32:1179-85. [DOI: 10.1097/meg.0000000000001628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
15 Medrano LM, Garcia-Broncano P, Berenguer J, González-García J, Jiménez-Sousa MÁ, Guardiola JM, Crespo M, Quereda C, Sanz J, Canorea I, Carrero A, Hontañón V, Muñoz-Fernández MÁ, Resino S; GESIDA 3603b Study Group. Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients. AIDS 2018;32:1095-105. [PMID: 29438197 DOI: 10.1097/QAD.0000000000001787] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
16 Nielsen MJ, Lehmann J, Leeming DJ, Schierwagen R, Klein S, Jansen C, Strassburg CP, Bendtsen F, Møller S, Sauerbruch T, Karsdal MA, Krag A, Trebicka J. Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS. Dig Dis Sci 2015;60:3456-64. [DOI: 10.1007/s10620-015-3783-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
17 Trebicka J, Reiberger T, Laleman W. Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. Visc Med. 2018;34:270-275. [PMID: 30345284 DOI: 10.1159/000490262] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
18 Trebicka J, Bastgen D, Byrtus J, Praktiknjo M, Terstiegen S, Meyer C, Thomas D, Fimmers R, Treitl M, Euringer W, Sauerbruch T, Rössle M. Smaller-Diameter Covered Transjugular Intrahepatic Portosystemic Shunt Stents Are Associated With Increased Survival. Clin Gastroenterol Hepatol 2019;17:2793-2799.e1. [PMID: 30940552 DOI: 10.1016/j.cgh.2019.03.042] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
19 Queck A, Bode H, Uschner FE, Brol MJ, Graf C, Schulz M, Jansen C, Praktiknjo M, Schierwagen R, Klein S, Trautwein C, Wasmuth HE, Berres ML, Trebicka J, Lehmann J. Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis. Front Immunol 2020;11:354. [PMID: 32218781 DOI: 10.3389/fimmu.2020.00354] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
20 Albillos A, Lario M, Álvarez-mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. Journal of Hepatology 2014;61:1385-96. [DOI: 10.1016/j.jhep.2014.08.010] [Cited by in Crossref: 470] [Cited by in F6Publishing: 424] [Article Influence: 67.1] [Reference Citation Analysis]
21 Jansen C, Möller P, Meyer C, Kolbe CC, Bogs C, Pohlmann A, Schierwagen R, Praktiknjo M, Abdullah Z, Lehmann J, Thomas D, Strassburg CP, Latz E, Mueller S, Rössle M, Trebicka J. Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. Hepatology 2018;67:1472-84. [PMID: 29059466 DOI: 10.1002/hep.29612] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 15.3] [Reference Citation Analysis]
22 Zhang Q, Steinle JJ. IGFBP-3 inhibits TNF-α production and TNFR-2 signaling to protect against retinal endothelial cell apoptosis. Microvasc Res 2014;95:76-81. [PMID: 25086184 DOI: 10.1016/j.mvr.2014.07.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
23 Trebicka J. Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close? J Hepatol. 2017;66:442-450. [PMID: 27984174 DOI: 10.1016/j.jhep.2016.10.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 9.6] [Reference Citation Analysis]
24 Trebicka J, Bork P, Krag A, Arumugam M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol 2021;18:167-80. [PMID: 33257833 DOI: 10.1038/s41575-020-00376-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]